Jenex Corp. - Marktführer mit viel Potenzial !!! - 500 Beiträge pro Seite

[BlackAngel]

Hier möchte ich eine Firma vorstellen, die zwar noch am Anfang ihrer Entwicklung steht, und doch schon sehr weit ist. Wir sprechen hier nämlich von einem Marktführer.



Jenex ist eine Firma, welche im Bereich Medizin und Medizintechnik Forschung und Entwicklung betreibt. Gegründet wurde die Firma 1999. Der Fokus der Firma liegt in der Forschung und Entwicklung der sogenannten Thermal Therapy Technologie. Das erste Produkt, was aus dieser Technologie heraus entwickel wurde ist Therapik. Dieses Produkt wurde in Canada und den USA zugelassen. Nachgewiesenermaßen stoppt dieses Produkt den Schmerz, Juckreiz und Entzündung, der durch Insektenstiche bzw. -bisse hervorgerufen wird.

Ein weiteres, vielleicht das interessanteste, ist die Technologie zur Verhütung von sogenannten Cold Sores (Herpes Simplex - Vireninfektion). Hier hat die Gesellschaft bewiesen, daß diese Technologie effektiv eingesetzt werden kann.
Cold Sores wird durch das Herpes Simplex Virus 1 (HSV-1) verursacht, welches in einer Art Ruhezusatnd für eine lange Zeit im Körper verbleiben kann.

Jenex hat die Exklusivrechte und Patente für die Thermal Therapy, welches für die Verhinderung von Cold Sores eingesetzt wird. Das Marktpotenzial eines solchen Produktes ist enorm, wenn man bedenkt, daß die Verbreitung dieser Art Krankheit in Nordamerika 80% der Bevölkerung betrifft. Für 20 - 40% der Bevölkerung sind dies schmerzhafte Ausbrüche, welche wiederkehrend sind und zu Hautveränderungen führen, die jederzeit auftreten können

Die verbreiteden Behandlungsmethoden, die aktuell angewandt weren, sind teure rezeptpflichtige Anti-Viren Medikamente, welche nur bedingt Wirkung erzielen und zusätzlich noch ungewollte Nebenwirkungenauslösen können. Thermal Therapy hingegen bietet eine natürliche Alternative, welche klinischerprobt sicher und effektiv ist. Zur Zeit gibt es kein anderes Produkt zur Verhütung von Cold Sores .

Damit nimmt Jenex in einem unterentwickeltem Markt, eine marktführende Position ein. Vorerst ist das Ziel der Firma, den kanadischen Markt zu durchdringen.

[BlackAngel]

Wie groß das Potenzial ist, erkennt man vielleicht an den nachfolgenden Erhebungen und Aussagen:

Market Size

“More than 135 million Americans older than the age of 12 are infected with herpes simplex virus type 1, according to a new study presented here at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy.”

Source: www.slackinc.com



“Roughly 58% of the U.S. population is affected by cold sores, and 24 percent, or 65 million people, suffer from recurrent sores.”

Source: www.zila.com



“Recurrent herpes simplex labialis is a common infection, affecting nearly one-third of the U.S. population.

Source: www.asmusa.org American Society of Microbiology



“One-in-five Americans suffers from cold sores each year. Most experience the pain, discomfort, and embarrassment of a cold sore two-to-three times a year, while some may suffer as many as 10 outbreaks a year.”

Source: Press Release – GSK Jan. 9, 2001



“An estimated 40 million American adults suffer from recurrent cold sores.”

Source: Press Release – GSK March 15, 2001



“It is estimated that up to 80% of the US population will be infected with HSV-1 at sometime in life, and that in up to 40% of the population, the initial infection will be followed by recurrent herpes labialis infections.”

Source: www.utexas.edu/pharmacy



“Herpes simplex virus type 1 causes recurrent herpes labialis, a common disease afflicting up to 40% of adults world wide.”

Source: Antimicrob Agents Chemother Oct. 2000



“a known history of herpes labialis was reported by 39.9 per 100”

Source: Study in France by Societe Francaise de Medecine Generale



“The prevalence of recurrent herpes labialis was 32.9%.

Source: American Journal Epidemiology March 1988



“Roughly 50 million Americans suffer from fever blisters or cold sores with more than 100 million episodes estimated annually.”

Source: www.denavir.com



“80% of the population carry HSV-1, 25% of those are recurrent.”

Source: www.cold-sore.com



“20% to 40% of HSV-1 carriers are recurrent.”

Source: www.webmed.com

[BlackAngel]

[BlackAngel]

Hier auch noch die letzte Empfehlung von gestern.

The Jenex Corporation Rated `Buy,`C$1.00 Fair Value by Investrend Affiliate Fundamental Research
5/11/04


NEW YORK, May 11, 2004 (PRIMEZONE via COMTEX) --
(Investrend Research Syndicate) Investrend Research affiliate Fundamental Research Corp. has rated the shares of The Jenex Corporation (TSX Venture Exchange:JEN) (Frankfurt/Berlin: JNX) a `Buy - 5 (Highly Speculative)`and placed a fair value of C$1.00 (current price:
$0.28). The following is a summary of the full 17-Page report which is available free at www.fundamentalresearchcorp.com.

The company owns the patents to thermal therapy technology devices that use heat to treat certain ailments. The most recent product resulting from this technology, which is in the final stages of development, is the InterceptorCS(tm). The hand-held device will use heat to prevent the symptoms of Herpes Labialis more commonly referred to as cold sores.

The company has approval in Canada to make the claim that the device prevents cold sores, and is expected to begin commercialization in Canada sometime in November 2004. The company is also seeking approval in Europe, the USA, and Australia. The report estimates that 40-80% of the population has the Herpes Simplex (HSV-1) Virus, and of these, 20-40% experience recurring outbreaks. Using these figures and the device`s estimated selling price of C$79.99, it was estimated that the potential market is C$4.9 billion in the U.S., Canada, and EU.

The report cautions that the company is in very early stages of commercialization, and certain milestones must be achieved in order to support the rating and fair value. Specifically, the company must: successfully gain regulatory approval in the USA and EU; secure a manufacturer (expected in 60 days); secure distribution agreements in the markets it intends to serve; and successfully market the product. Other risks include non-acceptance by consumers. Investors are advised to read the complete report including important disclosures, and further risk factors.

Fundamental Research Corp. is an affiliate of Investrend Research. Both subscribe to the `Standards for Independent Research Providers`at http://www.firstresearchconsortium.com

The fee for this coverage is $25,000, and the fee was paid by the company.

Complete information about this company is available at the company`s InvestorPower page at http://www.investrend.com/company/list.asp?sPathParam=yes , and the full report is available at: http://www.fundamentalresearchcorp.com/PDF/jenrating.pdf" target="_blank" rel="nofollow ugc noopener">http://www.fundamentalresearchcorp.com/PDF/jenrating.pdf and www.investrendresearch.com . Investors are advised to read disclosures carefully before trading in the equities of any enrolled company.

Anyone interested in receiving alerts regarding The Jenex Corporation research should email [e-mail] and [e-mail] with `JEN`in the subject line.

SOURCE: Investrend

INVESTMENT OPINION

The Jenex Corporation Mike Jenkins, President and CEO [phone] Email: [e-mail] Website: www.jenexcorp.com Fundamental Research Brian Tang [phone] Email [e-mail] Website: http://www.fundamentalresearchcorp.com Investrend Research Div., Investrend Communications, Inc. [phone] R. Hempel Email: [e-mail] Website:www.investrendresearch.com
(C) 2004 PRIMEZONE, All rights reserved.

[BlackAngel]

Competitive Technologies Obtains Exclusive Rights for Ready-To-Market Treatment for Insect Stings and Bites
5/17/04


FAIRFIELD, Conn., May 17, 2004 (PRIMEZONE via COMTEX) --
Competitive Technologies, Inc. (AMEX:CTT) announced today that it has signed an agreement with Ontario, Canada-based Jenex Corporation (TSX Venture Exchange:JEN) (Frankfurt:JNX) to exclusively license and commercialize Jenex`s patented thermal therapy technolo
gy, Therapik(tm). The exclusive license will cover various countries including Korea, China, Japan, Taiwan, Australia, Russia, Eastern Europe and India. In addition, CTT will have non-exclusive rights in all other countries. Therapik is a late-stage, ready-to-market medical device approved for use to provide temporary relief of the pain and itching resulting from insect stings and bites. The technology is approved by both the U.S. Food and Drug Administration and the Canadian Therapeutic Products Program. Patents in 15 countries, including the United States, Canada, Australia and Europe protect the technology.

`Therapik`s ready-to-market status provides a balance in our life science portfolio between early and late stage technologies and presents strong revenue opportunities for CTT going forward,`said Aris D. Despo, CTT`s VP Life Science Business Development. `Therapik`s proven capabilities make it an attractive and exciting addition to our portfolio. We will be offering market opportunities for this technology through licensed manufacturing agreements, and country-specific product distributors.`

The Therapik is a small, portable, hand-held, battery-powered device equipped with a carrying wrist strap. It delivers heat to a localized area of the body in order to relieve pain associated with stings from species that deliver thermolabile venom. Up to 20,000 species of insects and sea creatures are known to have thermolabile venom that may be destroyed by the application of heat. The most common sources of painful venomous stings are hymenopterous insects such as wasps, bees, and hornets, and sea creatures such as jellyfish, weaver fish and scorpion fish. The pain from such stings is produced by the release of histamine by cells in the organism that has been stung. Prompt destruction or inactivation of the venom interrupts the release of histamine, thus preventing or relieving the discomfort of the sting. In addition, the soothing heat also provides effective relief from the itching and irritation due to flea and mosquito bites and contact with stinging nettles.

`The Jenex agreement is evidence of CTT gaining outstanding technologies from our clients to move into the marketplace in line with our strategic plan for sustainable long term growth,`said John B. Nano, CTT`s President and CEO. `We have brought CTT to profitability, created a portfolio of quality technologies and formed strong global alliances. Utilizing our portfolio to satisfy customer needs, CTT is building a recurring revenue stream and strengthening shareholder value.`

About Jenex Corporation

Jenex Corporation, is a publicly traded Ontario, Canada-based medical device research and development company focused on developing unique consumer and healthcare products. Formed in 1999, Jenex is primarily concentrated on the field of thermal therapy technology. Visit Jenex`s website at http://www.jenexcorp.com

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life, digital, nano, and physical sciences developed by universities, companies and inventors. The global market for technology transfer services is estimated at $150 billion annually. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT`s website: http://www.competitivetech.net

Statements about the Company`s future expectations, including development and regulatory plans, and all other statements in this document other than historical facts are `forward-looking statements`within the meaning of applicable Federal Securities Laws and are not guarantees of future performance. These statements involve risks and uncertainties, including those set forth in Item 1 of the Company`s most recent Form 10-K and in CTT`s other filings with the SEC, and are subject to change at any time. The Company`s actual results could differ materially from these forward-looking statements. The Company undertakes no obligation to update publicly any forward-looking statement.

SOURCE: Competitive Technologies, Inc.

Strategic IR, Inc. Johnnie D. Johnson [phone] [phone], Fax Email: [e-mail] [e-mail]

(C) 2004 PRIMEZONE, All rights reserved.

[BlackAngel]

Signs Lisensing Agreement For Therapik Product In Asia
6/15/04


The Jenex Corporation announces that it has signed an exclusive multi-year agreement with Daeyang E&C of Korea, to manufacture and market Jenex`s patented Therapik(r) thermal therapy device in Asia. The Therapik(r) product is clinically proven and approved to provide relief of the pain and itch resulting from inse
ct stings and bites. The agreement was facilitated by Competitive Technologies Inc. (Amex: CTT), through a strategic partnership announced May 17, 2004 which allows CTT the right to negotiate exclusive licenses, on behalf of Jenex, to manufacture and market the Therapik(r) product in Asia and Western Europe. The Daeyang agreement includes South Korea, Peoples Republic of China, Japan, India and eighteen other Asian countries. This agreement will also offer Jenex the opportunity to acquire low cost quality product from Daeyang for distribution in other markets. The agreement provides for commercialization and recurring royalty fees for both Jenex and CTT.
The Therapik(r) device, approved by the U.S. Food and Drug Administration and the Canadian Therapeutic Products Programme is protected by patents in fifteen countries.

CTT`s VP Asia Business Development, Seung B. Oh said "This agreement resulted from the high-level interest produced for the Therapik(r) device from Korean companies during our recent presentation at the Korean technology forum. We believe Jenex`s medical device technology and Daeyang`s proven marketing, manufacturing and regulatory expertise will firmly establish Therapik(r)`s position in Asia."

Michael Jenkins, President & CEO of Jenex said "This is an important step towards accomplishing our world-wide licensing objectives for products developed from our Thermal Therapy technology. Our Therapik(r) product offers significant volume opportunities and revenue potential for Jenex. Daeyang E&C is a world class Korean public company and is highly recognized for their manufacturing and marketing capabilities in Asian markets. We are very pleased to have Daeyang as our Asian partner".

The Therapik(r) thermal therapy device is small, portable, hand-held and battery-powered. It delivers heat to a localized area of the body in order to relieve pain associated with stings from species that deliver thermolabile venom. Up to 20,000 species of insects and sea creatures are known to have thermolabile venom that may be destroyed by the application of heat. The most common sources of painful venomous stings are hymenopterous insects such as wasps, bees, and hornets, and sea creatures such as jellyfish, weaver fish and scorpion fish. The pain from such stings is produced by the release of histamines by cells in the organism that has been stung. Prompt destruction or inactivation of the venom interrupts the release of histamine, thus preventing or relieving the discomfort of the sting. In addition, the soothing heat also provides effective relief from the itching and irritation due to flea and mosquito bites and contact with stinging nettles.

About Daeyang E&C

Daeyang E&C is a publicly traded company in Korea and the market leader in its unique product segments. The company manufactures and markets various personal devices for medical and educational purposes. Daeyang E&C is able to access multiple business fields through the resources available from its affiliate Daeyang Venture Capital Ltd., also of Korea. Visit Daeyang`s website: http://www.dyenc.co.kr/

About Competitive Technologies Inc.

Competitive Technologies, established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life, digital, nano, and physical sciences developed by universities, companies and inventors. The global market for technology transfer services is estimated at $150 billion annually. CTT maximized the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT`s website: http://www.competitivetech.net/


About The Jenex Corporation

Headquartered in Burlington, Ontario, the Corporation owns a patented Thermal Therapy technology. Patents in fifteen countries, including the United States, Canada, Australia, and the E.E.C protect the technology. The first device developed from this technology was the Therapik(r) product, for insect stings and bites. Therapik(r) is approved by the U.S. FDA and the Canadian Therapeutic Products Programme. The second device, interceptCS is the first product proven and approved to prevent cold sores. Jenex has clearance to market the cold sore device in Canada with its approved claim, "For prevention and relief of the symptoms of herpes labialis (cold sores), such as blistering, lesions, inflammation, and discomfort. Also helps alleviate the embarrassment that is typically associated with herpes labialis (cold sore) outbreaks". The Corporation is preparing for the launch of interceptCS in the Canadian market in late 2004. Regulatory approvals are being pursued for USA, Europe and Australia. The HSV-1 virus that causes cold sores, is endemic in North America, and is estimated to affect 80% of the population. As the only product clinically proven to prevent the outbreak of cold sores, the Corporation`s thermal therapy product has the potential to dominate a large and underdeveloped market. More information about the Corporation can be found at: www.jenexcorp.com.

Forward Looking Statements

The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the accuracy or the contents of this press release. Certain information included in this press release is forward-looking and is subject to important risks and uncertainties. The results or events predicted in these statements may differ materially from actual results or events.



CONTACT: TEL: [phone] The Jenex Corporation, Michael Jenkins - President